Loading stock data…
Ascendis Pharma A/S (ASND)
$260.75-0.83 (-0.32%)
Pre-Market$261.31+0.56 (+0.21%)· Last close Jun 26
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ascendis Pharma A/S in the Healthcare sector is trading at $260.75 with a market capitalization of $17.1B. Wall Street consensus targets $291.55 (18 analysts), implying a +11.8% move over the next 12 months. The stock is currently near its 52-week high of $271.89, remaining 19.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $246.60M↓ | $247.50M↑ | $213.63M↑ | $158.04M↑ | $100.95M |
| Gross Profit | $229.09M↑ | $223.90M↑ | $191.28M↑ | $126.60M↑ | $83.44M |
| Operating Income | $24.81M↑ | $6.44M↓ | $11.00M↑ | -$52.95M↑ | -$104.21M |
| Net Income | $629.34M↑ | -$33.56M↑ | -$60.99M↓ | -$38.85M↑ | -$94.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
30.32
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
101.63%
Volume
Today's trading volume
4.45M
Recent News
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week
European equities traded in the US as American depositary receipts were trending higher late Friday
Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years
Ascendis Pharma (ASND) said late Thursday that five-year data from its Phase 2 PaTH Forward trial sh
Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy
Ascendis Pharma (NASDAQ:ASND) is one of the most profitable growth stocks to buy. On May 7, Ascendis Pharma reported strong financial results for Q1 2026, reaching a total revenue of €247 million. This growth was primarily driven by YORVIPATH, which generated €197 million, alongside €44 million from SKYTROFA. Additionally, the company announced an agreement to […]
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness
Event context and recent price moves Ascendis Pharma (NasdaqGS:ASND) has recently drawn investor attention after the stock fell about 4% in a day and is down roughly 4% over the past week and 12% over the past month. See our latest analysis for Ascendis Pharma. At a share price of $210.45, Ascendis Pharma’s recent pullback, including a 1-month share price return of down 11.82% and year to date share price return of down 14.24%, points to fading near term momentum despite earlier gains. If you...